Related Experiment Video
Updated: Jun 22, 2026
09:25
Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
Published on: January 10, 2015
Smoking affects eotaxin levels in asthma patients
Algirda Krisiukeniene1, Agne Babusyte, Kristina Stravinskaite
1Department of Pulmonology and Immunology, Kaunas University of Medicine, Kaunas, Lithuania.
Summary
Cigarette smoking in asthma patients elevates sputum eotaxin-1 and eotaxin-2 levels, potentially altering airway inflammation. These eotaxins correlate with both eosinophils and neutrophils, suggesting a complex inflammatory response in smokers.
Area of Science:
- Pulmonary Medicine
- Immunology
- Respiratory Research
Background:
- Chronic airway inflammation is a key feature of asthma.
- Cigarette smoking can impact asthma's inflammatory profile, severity, and treatment response.
Purpose of the Study:
- To investigate the influence of cigarette smoking on eotaxin-1, eotaxin-2, eotaxin-3, and IL-5 levels in stable mild/moderate asthma patients.
Main Methods:
- Compared 45 steroid-naive asthmatics (smokers vs. never-smokers) with 23 healthy controls.
- Analyzed eotaxin and IL-5 concentrations in serum, sputum, and bronchoalveolar lavage (BAL) using ELISA.
- Performed differential cell counts on sputum and BAL cytospins.
Main Results:
- Asthmatic smokers had higher sputum eotaxin-1 than non-smoker asthmatics.
- BAL eotaxin-1 in non-smokers correlated with eosinophils and neutrophils.
- Sputum neutrophils and eosinophils in smokers correlated with sputum eotaxin-2.
- IL-5 levels were higher in serum and sputum of never-smokers compared to smokers.
Conclusions:
- Asthmatic smokers exhibit elevated sputum eotaxin-1 and serum/sputum/BAL eotaxin-2 without increased eosinophils.
- Eotaxin levels correlated with both eosinophils and neutrophils in various compartments.
- Smoking may stimulate eotaxin production, influencing airway inflammation in asthma.
Related Concept Videos
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:29Asthma-I: Introduction
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...